WJ Interests’s TG Therapeutics TGTX Stock Holding History

WJ Interests’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,000	Closed	-$35.5K	–	58
2022 Q4	$35.5K	Buy	+3,000	New	+$21.8K	0.03%	43

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WJ Interests's TGTX Position: Q1 2023 in Review

WJ Interests sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 3,000 shares — an estimated $35.5K sold.

WJ Interests first reported a position in TGTX in Q4 2022 and held it in 1 quarter. The position peaked at $35.5K in Q4 2022. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

WJ Interests reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
WJ Interests sold 3,000 TG Therapeutics shares in Q1 2023, an estimated $35.5K.
WJ Interests first reported a position in TG Therapeutics in Q4 2022 and held it in 1 quarter.
WJ Interests's TG Therapeutics position peaked at $35.5K in Q4 2022.
214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on WJ Interests's 13F filing for Q1 2023, filed 13 Apr 2023.